



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
FEB 03 2003  
TECH CENTER 1600/2900

In re Application of: )  
)  
A. PEYMAN et al. )  
)  
Application No.: 09/554,267 ) Group Art Unit: 1635  
)  
Filed: July 24, 2000 )  
) Examiner: J. ZARA  
For: ANTISENSE OLIGONUCLEOTIDES )  
AGAINST TENASCIN FOR )  
TREATING VITILIGO )

Assistant Commissioner for Patents  
Washington, D.C. 20231

AMENDMENT

Sir:

In response to the Final Office Action dated January 2, 2002, and the Advisory Action dated July 11, 2002, please amend this application as follows:

IN THE CLAIMS:

Please cancel claims 24, 25, and 36-40 without prejudice to, or disclaimer of, the subject matter contained therein.

Please amend claims 26, 27, 32, 33, and 42-44 as follows:

26. (Amended) An oligonucleotide or physiologically tolerable salt thereof, comprising a sequence selected from SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID